Securities code: Betta Pharmaceuticals Co.Ltd(300558) securities abbreviation: Betta Pharmaceuticals Co.Ltd(300558) Announcement No.: 2022043 Betta Pharmaceuticals Co.Ltd(300558)
First quarter report 2022
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions. Important content tips: 1 The board of directors, the board of supervisors, directors, supervisors and senior managers guarantee that the quarterly report is true, accurate and complete without false records, misleading statements or major omissions, and bear individual and joint legal liabilities. 2. The person in charge of the company, the person in charge of accounting and the person in charge of the accounting organization (Accounting Supervisor) declare that they guarantee the authenticity, accuracy and completeness of the financial information in the quarterly report. 3. The first quarter report was unaudited. 1、 Main financial data (I) main accounting data and financial indicators the company does not need to retroactively adjust or restate the accounting data of previous years
Increase or decrease in the reporting period compared with the same period of the previous year
Operating income (yuan): 5847056320461856158132 – 5.47%
Net profit attributable to shareholders of listed company (yuan): 836789288914774567333 – 43.36%
Net profit attributable to shareholders of listed companies after deducting non recurring profit and loss 745474572114037012242 – 46.89% (yuan)
Net cash flow from operating activities (yuan) 29306885707755131252 – 62.21%
Basic earnings per share (yuan / share) 0.20 0.36 – 44.44%
Diluted earnings per share (yuan / share) 0.20 0.35 – 42.86%
Weighted average return on net assets 1.81%, 3.51% – 1.70%
Increase or decrease at the end of the reporting period compared with the end of the previous year
Total assets (yuan): 658433049366627143207694 4.99%
Owner’s equity attributable to shareholders of listed company (yuan): 467171960498456088793457 2.43%
（2） Non recurring profit and loss items and amounts
Unit: Yuan
Amount of the project in the reporting period
Gains and losses on disposal of non current assets (including the write off part of the provision for asset impairment) -7044733
Government subsidies included in the current profits and losses (except those closely related to the company’s normal business, in line with national policies and regulations, and continuously enjoyed according to a certain standard quota or quantity according to 1129897611) hold trading financial assets and trading assets in addition to the effective hedging business related to the company’s normal business
Profit and loss from changes in fair value of financial liabilities, and investment income from disposal of trading financial assets, trading financial liabilities and 48490412 available for sale financial assets
Other profit and loss items in line with the definition of non recurring profit and loss -113827380
Less: income tax impact 143793299
Influence amount of minority shareholders’ equity (after tax) 575443
Total 913147168
The company has no specific circumstances of other profit and loss items that meet the definition of non recurring profit and loss. The company does not define the non recurring profit and loss items listed in the explanatory announcement on information disclosure of companies offering securities to the public No. 1 – non recurring profit and loss as recurring profit and loss items.
（3） Changes and reasons of main accounting data and financial indicators
Explanation of the reasons for the increase or decrease of the ending balance of the items in the consolidated balance sheet
Trading financial assets 20100550685 Principal Guaranteed bank financial products measured at fair value during the reporting period shall be recovered by – 100.00%.
Accounts receivable 3056944568416893224595 80.96% increased at the end of the reporting period.
Prepayment 45967097653056252585 50.40% increase in prepaid R & D related expenses at the end of the reporting period.
The investment in other equity instruments was 8029196748733629502635. During the reporting period, new investments were made in Wuhan Heyuan Biotechnology Co., Ltd. and 138.75% in Zhejiang shimai Pharmaceutical Co., Ltd.
Deferred income tax assets 30975005505506211030 – 43.75% decrease in deferred income tax assets formed by uncovered losses at the end of the reporting period.
Short term loan 15000000000 new bank loan during the reporting period.
Accounts payable 2449714306143118733214 – 43.19% of the project accounts payable at the beginning of the reporting period.
The employee salary payable is 585981989813701212486 – 57.23%, and the annual bonus payable at the beginning of the reporting period is paid.
Long term loan 28000000000 new bank loans during the reporting period.
Other comprehensive income 47966451987464100094 – 35.74% changes in the fair value of other equity instrument investments during the reporting period.
Reasons for the increase or decrease of current period amount and previous period amount of consolidated income statement items
The operating cost was 7043939516, 3935553389, and 78.98% of the drug sales increased during the reporting period.
Administrative expenses 133075117616369516229 108.92% share based payment related expenses increased significantly during the reporting period.
836789288914774567333% – 43.36% attributable to the owner of the parent company, mainly due to the impact of share based payment on net profit of 61.22 million yuan.
Net profit of
Reasons for the increase or decrease of the amount in the current period and the amount in the previous period of the items in the consolidated cash flow statement
The cash generated from operating activities was 29306885707755131252% – 62.21%. The cash inflow from drug sales decreased during the reporting period.
Net flow
The cash generated from financing activities was 42975663980 -197139000 and 2189968% of the new bank loans during the reporting period.
Net flow
2、 Shareholder information (I) total number of ordinary shareholders, number of preferred shareholders whose voting rights have been restored and shareholding of the top ten shareholders
Unit: shares
Total number of common shareholders at the end of the reporting period
29910 total number of prior shareholders (if any) 0
Shareholding of top 10 shareholders
Shareholder name shareholder nature shareholding proportion shareholding quantity holding limited sale condition pledge, marking or freezing
Number of shares in stock status
Ningbo Kaiming Investment Management Co., Ltd
Management partnership (limited partnership with 19.27% domestic non-state-owned legal person 800640000 pledge 40510000)
Zhejiang Jihe venture domestic non-state-owned legal person 13.08% 543240000
Wenzhou terexi Venture Capital Co., Ltd
Business management partnership domestic non-state owned legal person 6.93% 287970610
(limited partnership)
Wang overseas natural person 3.73% 154945640
Yinxiang Zhejiang Beicheng Investment Management Co., Ltd
Management partnership (with domestic non-state-owned legal person) 3.54% 147135310
Equity
(Hong Kong) Co., overseas legal person 2.60% 10800000
Limited
HKSCC overseas legal person 2.59% 107750960
limited company
whole
